Opinion

Video

Future of BCG in NMIBC

Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the future of first-line treatment be a noninfectious agent that would be easier to develop and include more data.

Video content above is prompted by the following:

  • Given these recent advances and emerging agents, do you think BCG monotherapy will remain the first-line treatment for intermediate-risk and high-risk disease?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
DNA helix | Image Credit: © Radomir Jovanovic - stock.adobe.com
Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
1 expert is featured in this series.
1 expert is featured in this series.
Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
© 2025 MJH Life Sciences

All rights reserved.